1043 related articles for article (PubMed ID: 35676620)
1. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
2. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab for induction and maintenance of remission in Crohn's disease.
Hui S; Sinopoulou V; Gordon M; Aali G; Krishna A; Ding NS; Boyapati RK
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013611. PubMed ID: 37458279
[TBL] [Abstract][Full Text] [Related]
4. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
6. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
8. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
[TBL] [Abstract][Full Text] [Related]
9. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
Hoffmann P; Krisam J; Stremmel W; Gauss A
Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
[TBL] [Abstract][Full Text] [Related]
11. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
Cohen NA; Plevris N; Kopylov U; Grinman A; Ungar B; Yanai H; Leibovitzh H; Isakov NF; Hirsch A; Ritter E; Ron Y; Shitrit AB; Goldin E; Dotan I; Horin SB; Lees CW; Maharshak N
United European Gastroenterol J; 2020 Nov; 8(9):1076-1085. PubMed ID: 32807038
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Hyams JS; Turner D; Cohen SA; Szakos E; Kowalska-Duplaga K; Ruemmele F; Croft NM; Korczowski B; Lawrence P; Bhatia S; Kadali H; Chen C; Sun W; Rosario M; Kabilan S; Treem W; Rossiter G; Lirio RA
J Crohns Colitis; 2022 Aug; 16(8):1243-1254. PubMed ID: 35301512
[TBL] [Abstract][Full Text] [Related]
16. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
[TBL] [Abstract][Full Text] [Related]
18. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
